Company Performance - Thermo Fisher Scientific reported quarterly earnings of 6.10pershare,exceedingtheZacksConsensusEstimateof5.93 per share, and up from 5.67pershareayearago[1]−Thecompanyachievedrevenuesof11.4 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.31%, compared to 10.89billioninthesamequarterlastyear[3]−Overthelastfourquarters,ThermoFisherhasconsistentlysurpassedconsensusEPSestimatesfourtimesandrevenueestimatesthreetimes[2][3]MarketPerformance−ThermoFishershareshaveincreasedapproximately9.25.33 on revenues of 10.7billion,andforthecurrentfiscalyear,itis23.11 on revenues of $44.38 billion [8] Industry Outlook - The Medical - Instruments industry, to which Thermo Fisher belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook [9] - The performance of Thermo Fisher's stock may be influenced by the overall industry outlook, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [9]